Latest:
Additional Biomarkers Are Needed to Inform ADC Selection in NSCLC
Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Andreas M. Kaiser, MD
Andreas M. Kaiser, MD, is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope.
Latest:
Dr Kaiser on Advances With Minimally Invasive Surgery in CRC
Andreas M. Kaiser, MD, discusses the benefits of minimally invasive surgery for patients with colorectal cancer.
Natalie S. Callander, MD, University of Washington Carbone Cancer Center
Latest:
CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
Avan Armaghani, MD
Latest:
Dr Armaghani on the Investigation of De-Escalated Treatment Approaches in TNBC
Avan Armaghani,cdiscusses the feasibility of de-escalating treatment in triple-negative breast cancer, as well as planned or ongoing research investigating this approach in the neoadjuvant and metastatic settings.
Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute
Latest:
Looking Ahead and Key Takeaways
Elizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.
Chinmay Jani, MD
Chinmay Jani, MD, is the chief fellow of hematology and oncology at the University of Miami Sylvester Comprehensive Cancer Center.
Latest:
Dr Jani on the Inclusion of PRO End Points in Lung Cancer Clinical Trials
Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.
Thomas W. LeBlanc, MD, MA
Latest:
The Future of Lower-Risk MDS: Closing Thoughts and Unmet Needs
Panelists discuss how community oncologists can apply key takeaways from this clinical scenario in their practice, emphasizing the importance of collaborating with academic clinicians for optimal patient identification and treatment selection in the evolving landscape of lower-risk MDS management.
Pankit Vachhani, MD
Pankit Vachhani, MD, is an associate professor of medicine and associate scientist of experimental therapeutics at the University of Alabama at Birmingham.
Latest:
Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study
Presented by Dr. Pankit Vachhani, this updated analysis of the PIONEER trial demonstrated that long-term treatment with avapritinib led to sustained symptom relief, improved quality of life, and maintained a favorable safety profile over approximately 3 years in patients with indolent systemic mastocytosis.
Liliana Bustamante, MD
Liliana Bustamante, MD, is a medical oncologist and hematologist at Florida Cancer Specialists & Research Institute
Latest:
Peer Support, Adaptability, and Self-Confidence Are Hallmarks of Successful Oncology Careers: With Liliana Bustamante, MD; and Jessica Stine, MD
Drs Bustamante and Stine discuss their journeys toward oncology careers, the importance of peer mentorship, and the evolving nature of work-life balance.